Cat. No.: HY-N1472

Levistolide A

5 Cited Publications

Avis client

Based on 5 publication(s) in Google Scholar

Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.34%
CAS No.: 88182-33-6
Formule: C₂₄H₂₈O₄
Masse moléculaire:380.48

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Levistolide A Chemical Structure

CAS No.: 88182-33-6

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform PPAR :

Voir tous les produits spécifiques à Isoform GSK-3 :

Voir tous les produits spécifiques à Isoform Ras :

Voir tous les produits spécifiques à Isoform TGF-β Receptor :

In Vitro

Levistolide A (50, 100 μM; 24 h) induces apoptosis in colon cancer cells by promoting ROS generation and mediating the endoplasmic reticulum stress pathway^[1].
Levistolide A (1.1, 3.3, 10 μg/mL) activates peroxisome proliferator activated receptor gamma (PPARγ) in N2a/APP695swe cells and reduces tau hyperphosphorylation through the GSK3 α/β pathway, thereby reducing the production and aggregation of β - amyloid protein (A β)^[2].
Levistolide A (20-80 μM; 36 h) can inhibit the replication of Porcine Epidemic Diarrhea Virus (PEDV) by inducing ROS generation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1].

Cell Line:

HCT116 human colon cancer cells
Concentration:

50, 100 μM
Incubation Time:

24 h
Result:

Promoted cell apoptosis in a dose-dependent manner.

Western Blot Analysis^[2].

Cell Line:

N2a/APP695swe cells
Concentration:

1.1, 3.3, 10 μg/mL
Incubation Time:
Result:

Promoted the protein expression of PPAR γ in cells.

RT-PCR^[3].

Cell Line:

Vero cells
Concentration:

20-80 μM
Incubation Time:

36 h
Result:

Inhibited the generation of PEDV RNA.

In Vivo

Levistolide A (2 mg/kg; once every two days; i.p.) can improve memory deficits and cognitive abilities in Alzheimer's disease mice, and reduce inflammatory responses in the brain^[2].
Levistolide A (0.5-2 mg/kg; once every two days; 4 weeks; i.p.) improves renal fibrosis and injury in 5/6 nephrectomy (Nx) mice by inhibiting the expression of key molecules in the RAS, TGF - β 1/Smad, and MAPK pathways^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Amyloid precursor protein/presenilin 1 (APP/PS1) transgenic (Tg) mouse model^[2].
Dosage:

2 mg/kg
Administration:

Intraperitoneal injection (i.p.); once every two days
Result:

Improved memory impairment and cognitive decline in APP/PS1 Tg mice, and reduced the generation of A β and inflammatory response in the mouse brain.

Animal Model:

5/6 nephrectomy (Nx) mice ^[4].
Dosage:

0.5-2 mg/kg
Administration:

Intraperitoneal injection (i.p.); once every two days; 4 weeks
Result:

Inhibited expression levels of renin and Ang II, inflammation and oxidative stress and improved renal fibrosis.

Chemical Information

CAS No. 88182-33-6
Appearance Solid
Masse moléculaire 380.48
Formule C₂₄H₂₈O₄
Color White to off-white
SMILES

O=C(O/C([C@@]1(CC2)[C@]34[H])=C\CCC)C1=C[C@]2([H])[C@]3([H])CCC5=C4C(O/C5=C\CCC)=O
Structure Classification
- Others
Initial Source
- Plants
- Umbelliferae
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All

Sort by:

Journal Impact Factor

Sens Actuators B Chem

2024 Nov 1.
Microchem J

2024 Dec.
Bioorg Chem

Exploring the mechanism of Levistolide A in the treatment of lung cancer cells based on network analysis, molecular docking and experimental validation. [Abstract]

2025 Sep 16:165:109002. PMID: 40974659
Viruses

Levistolide A Inhibits PEDV Replication via Inducing ROS Generation. [Abstract]

2022 Jan 27;14(2):258. PMID: 35215851
Curr Issues Mol Biol

Levistolide A Alleviates Myocardial Ischemia-Reperfusion Injury Partly by Improving Calcium Homeostasis via the ADORA2B/cAMP/PKA/PLB/SERCA2α Signaling Axis. [Abstract]

2026 Jan 23;48(2):125. PMID: 41751389

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (262.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6283 mL

13.1413 mL

26.2826 mL

5 mM

0.5257 mL

2.6283 mL

5.2565 mL

10 mM

0.2628 mL

1.3141 mL

2.6283 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.57 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC/saline water

Solubility: 3.33 mg/mL (8.75 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Yang Y, et al. Levistolide A Induces Apoptosis via ROS-Mediated ER Stress Pathway in Colon Cancer Cells. Cell Physiol Biochem. 2017;42(3):929-938. [Content Brief]

[2]. Qu X, et al. Levistolide A Attenuates Alzheimer's Pathology Through Activation of the PPARγ Pathway. Neurotherapeutics. 2021 Jan;18(1):326-339. [Content Brief]

[3]. Zeng W, et al. Levistolide A Inhibits PEDV Replication via Inducing ROS Generation. Viruses. 2022 Jan 27;14(2):258. [Content Brief]

[4]. Aobulikasimu N, et al. Levistolide A ameliorates fibrosis in chronic kidney disease via modulating multitarget actions in vitro and in vivo. Life Sci. 2023 May 1;320:121565. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6283 mL	13.1413 mL	26.2826 mL	65.7065 mL
	5 mM	0.5257 mL	2.6283 mL	5.2565 mL	13.1413 mL
	10 mM	0.2628 mL	1.3141 mL	2.6283 mL	6.5706 mL
	15 mM	0.1752 mL	0.8761 mL	1.7522 mL	4.3804 mL
	20 mM	0.1314 mL	0.6571 mL	1.3141 mL	3.2853 mL
	25 mM	0.1051 mL	0.5257 mL	1.0513 mL	2.6283 mL
	30 mM	0.0876 mL	0.4380 mL	0.8761 mL	2.1902 mL
	40 mM	0.0657 mL	0.3285 mL	0.6571 mL	1.6427 mL
	50 mM	0.0526 mL	0.2628 mL	0.5257 mL	1.3141 mL
	60 mM	0.0438 mL	0.2190 mL	0.4380 mL	1.0951 mL
	80 mM	0.0329 mL	0.1643 mL	0.3285 mL	0.8213 mL
	100 mM	0.0263 mL	0.1314 mL	0.2628 mL	0.6571 mL

Keywords

Levistolide A

5 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Levistolide A

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Levistolide A

Voir tous les produits spécifiques à Isoform PPAR

Voir tous les produits spécifiques à Isoform GSK-3

Voir tous les produits spécifiques à Isoform Ras